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of ongoing neuroinﬂammation, in which astrocytes play a
signiﬁcant role. Following noxious stimuli, increased
inﬂammatory receptor activity, inﬂuences in Na+/K+-ATP-
ase activity and actin ﬁlament organization occur within
the central nervous system. In astrocytes, the Ca2+ signal-
ing system, Na+ transporters, cytoskeleton, and release of
pro-inﬂammatory cytokines change during inﬂammation.
The aim of this study was to restore these cell parameters
in inﬂammation-reactive astrocytes. We found that the com-
bination of (1) endomorphin-1, an opioid agonist that stimu-
lates the Gi/o protein of the l-opioid receptor; (2) naloxone,
an opioid antagonist that inhibits the Gs protein of the l-opi-
oid receptor at ultralow concentrations; and (3) levetirace-
tam, an anti-epileptic agent that counteracts the release of
IL-1b, managed to activate the Gi/o protein and Na
+/K+-ATP-
ase activity, inhibit the Gs protein, and decrease the release
of IL-1b. The cell functions of astrocytes in an inﬂammatory
state were virtually restored to their normal non-inﬂamma-
tory state and it could be of clinical signiﬁcance and may
be useful for the treatment of long-term pain.
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INTRODUCTION
During injury, pain can be dissociated from its normal
physiological role and can persist for a long period of
time, even after the primary noxious stimulus has
passed (McMahon and Malcangio, 2009; Milligan and
Watkins, 2009; Gao and Ji, 2010). The mechanisms
behind insuﬃciently healed neuroinﬂammation and how
the neuronal and non-neuronal activities evoked by
painful stimuli and inﬂammation are processed in the
brain and throughout the central nervous system (CNS)
are not well understood.
Under conditions that lead to neuroinﬂammation in the
nervous system, Ca2+ signaling in the astrocyte network
is overactivated, which triggers the activation of
astrocytes and microglia (Strokin et al., 2011). Several
receptors are inﬂuenced, and the expression of some
receptors, such as Toll-like receptor 4 (TLR4)
(Forshammar et al., 2011; Stevens et al., 2013), are
increased, whereas the responses of other receptors,
such as opioid receptors (El-Hage et al., 2006; Block
et al., 2012), are changed. In addition, there is an
increased release of glutamate into the neural synapse,
where astrocytes are the predominant players in
clearing the extracellular space. The astrocyte uptake of
excessive extracellular glutamate by membrane-bound
glutamate transporters, such as GLAST and GLT-1,
play a critical role in preventing glutamate excitotoxicity
(Zhao et al., 2012). In addition, metabotropic and
ionotropic glutamate receptors will be excited. The
astrocyte metabotropic receptor mGluR5 activates Gq
protein-coupled receptors, resulting in increased
intracellular Ca2+ release (Hansson, 1994; Bradley
et al., 2009), whereas the N-methyl-D-aspartic acid
(NMDA) receptor subunit NR2B is expressed in states
of increased neuronal excitability (Krebs et al., 2003)
and in inﬂammation-reactive astrocytes (Lundborg et al.,
2011; Ge´rard and Hansson, 2012). These changes in
the glial cells can lead to pathogenic chronic
neuroinﬂammation. Subsequently the neurons change
their excitability and signaling.
Endomorphin-1, a selective endogenous l-opioid
receptor agonist, is capable of interacting with the
pertussis toxin-sensitive Gi/G0 protein (Connor and
Christie, 1999), and increases the activity of Na+/K+-
ATPase in vitro (Horvath et al., 2003). Similar results
have been observed with morphine, which indirectlyC BY license.
Fig. 1. Culture stained for OX42, a marker for microglial cells
(green), and for GFAP, a marker for astrocytes (red). (A) Very few
microglia were found in the co-cultured astrocytes. (B) Also very few
microglia were found after treatment with LPS for 24 h. Scale
bar = 50 lm. Representative images are presented. (For interpreta-
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receptors and Gi/G0 protein (Masocha et al., 2002).
Naloxone in ultralow picomolar concentrations has
potent antagonistic actions on the excitatory l-opioid
receptor Gs protein. Higher concentrations antagonize
both excitatory Gs proteins, and inhibitory Gi/G0
proteins. As a consequence ultralow picomolar
concentrations of naloxone enhance the analgesic
eﬀects of l-opioid receptor agonists (Crain and Shen,
1995; Wang et al., 2005; Tsai et al., 2009). Naloxone
also modulates the Na+/K+-ATPase activity
(Forshammar et al., 2011). Ultralow concentrations of
naloxone stimulate the activity of Na+/K+-ATPase
through activation of phospholipase C resulting in
increases in intracellular Ca2+ release. Higher
concentrations have antagonistic eﬀects on the Na+/
K+-ATPase activity (Zhang et al., 2008; Forshammar
et al., 2011).
Levetiracetam, an eﬀective anti-epileptic drug, has in
inﬂammation-reactive astrocyte models been shown to
restore functional gap junction coupling (Stienen et al.,
2010) by increasing the expression of connexin 43, the
predominant gap junction protein, and decrease the
enhanced IL-1b level (Haghikia et al., 2008).
The aim of this study was to use endomorphin-1,
naloxone, and levetiracetam to evaluate if they could
counteract the increased astrocyte Ca2+ signaling,
downregulation of the Na+/K+-ATPase activity,
disorganization of the cytoskeleton, and increased
release of IL-1b. These agents might have a potential to
restore cell functions that are altered by inﬂammation in
astrocytes back to a normal non-inﬂammatory level.tion of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)EXPERIMENTAL PROCEDURES
In this study, the in vitro model involved astrocytes co-
cultured with brain endothelial cells (Hansson et al.,
2008). The biological rationale for co-culturing
astrocytes with endothelial cells is that astrocytes are
aﬀected by substances that are released from the
capillary endothelial cells of the BBB (blood–brain
barrier) (Huber et al., 2001). These interactions are
essential for a functional neurovascular system, where
also the neurons take part (Abbott et al., 2006; Willis
and Davis, 2008). The endothelial cells are not directly
in physical contact with the astrocytes in vitro, and the
interaction in the model is induced by the shared
medium. The co-cultured astrocytes are morphologically
diﬀerentiated by long, slender processes, and they
exhibit greater Ca2+ responses and cytokine release
than monocultured astrocytes. The l-opioid receptor is
also better expressed in the co-cultured astrocytes
(Hansson et al., 2008), as well as the TLR4
(Forshammar et al., 2011). Furthermore, the cultures
have very few microglial cells, visualized with OX42
(Fig. 1A), as well as after treatment with
lipopolysaccharide (LPS) for 24 h (Fig. 1B).Chemicals
All chemicals were obtained from Sigma–Aldrich (St.
Louis, MO, USA) unless otherwise stated.The experimental protocols were approved by the
Ethics Committee in Gothenburg for Laboratory Animals
(Nos. 205-2010; 211-2010).
Primary astrocyte cultures
The primary astrocyte cultures were prepared from
newborn rat cerebral cortices (Charles River, Sulzfeldt,
Germany) and cultured on glass coverslips (Nr 1,
diameter 20 mm, BergmanLabora, Stockholm, Sweden)
as described by Hansson et al. (2008).
Microvascular endothelial primary cultures
Brain capillary fragments were isolated from male
Sprague–Dawley rats, cerebral cortices (Charles River,
225–250 g), and the endothelial cells were cultured
according to the protocol of Hansson et al. (2008).
Astrocytes co-cultured with adult rat brain
microvascular primary cultures
The experimental astrocytes were obtained after co-
cultivation with primary brain microvascular endothelial
cultures and primary astrocyte cultures. Astrocyte
cultures at 6 d in vitro were co-cultured with newly
prepared microvascular cultures. The endothelial cells
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cells from the two diﬀerent cultures were never in
contact. The cells were grown together for 9–11 d. At
the time of the experiments, the astrocyte cultures were
15–17 d old, including 9–11 d of co-cultivation. The
endothelial cells were removed before the experimental
procedure (Hansson et al., 2008).Immunocytochemistry
The cells were ﬁxed with 4% paraformaldehyde (Bie &
Berntsen, Herlev, Denmark) for 10 min and washed
twice with phosphate-buﬀered saline (Invitrogen)
containing 1% bovine serum albumin (PBS–BSA). The
cells were permeabilized with PBS–BSA containing
0.05% saponine (PBS–BSA–Sap) for 20 min. Thereafter
the cells were incubated for 1 h with a cocktail of rabbit
polyclonal antibody against glial ﬁbrillary acidic protein
(GFAP) (Dako, Glostrup, Denmark) and a mouse
monoclonal antibody against OX42 (Serotec, Oxford,
UK). Both antibodies were diluted 1:100 in PBS–BSA–
Sap.
The cells were washed with PBS–BSA–Sap for
3  5 min and then incubated with a mixture of FITC
conjugated F(ab0)2 fragment donkey anti-mouse IgG and
a Dylight 594 conjugated F(ab0)2 fragment donkey anti-
rabbit IgG secondary antibodies (Jackson
ImmunoResearch Europe Ltd, Suﬀolk, UK), both diluted
1:150. The cells were washed with PBS–BSA–Sap for
3  5 min and ﬁnally rinsed with PBS. The cover slips
were mounted on microscope slides with a ﬂuorescent
mounting medium (Dako) and viewed in a Nikon Eclipse
80i microscope. Pictures were taken with a Hamamatsu
C5810 color intensiﬁed 3CCD camera.Calcium imaging
The astrocytes were incubated at room temperature with
the Ca2+-sensitive ﬂuorophore probe Fura-2/AM
(Invitrogen Molecular Probes, Eugene, Oregon, USA)
for 20 min (8 ll in 990 ll Hank’s HEPES-buﬀered saline
solution [HHBSS], containing 137 mM NaCl, 5.4 mM
KCl, 0.4 mM MgSO4, 0.4 mM MgCl2, 1.26 mM CaCl2,
0.64 mM KH2PO4, 3.0 mM NaHCO3, 5.5 mM glucose,
and 20 mM HEPES dissolved in distilled water, pH 7.4).
The ﬂuorophore probe was dissolved with 40 ll of
dimethyl sulfoxide (DMSO) and 10 ll of pluronic acid
(Molecular Probes, Leiden, The Netherlands). After
incubation, the cells were rinsed three times with
HHBSS before exposure to stimulators for 30 s. The
cells were incubated with LPS (10 ng/ml) for 24 h.
Naloxone (1012 M), endomorphin-1 (106 M), and
levetiracetam (104 M) were applied 3.5 min before
glutamate (104 M). The experiments were performed at
room temperature using a Ca2+ imaging system with
Simple PCI software (Compix Inc., Imaging Systems,
Hamamatsu Photonics Management Corporation,
Cranberry Twp, PA, USA) and an inverted
epiﬂuorescence microscope (Nikon ECLIPSE TE2000-
E) with a 20 (NA 0.45) ﬂuorescence dry lens and a
Polychrome V monochromator-based illumination
system (TILL Photonics GMBH, Munich, Germany). Thevarious substances were applied using a peristaltic
pump (Instech Laboratories, Plymouth Meeting, PA,
USA) at an approximate rate of 600 ll/min. One min
after the start of the experiment, the stimulating
substance was pumped into the pump tubes for 30 s.
The substance took approximately 60 s to reach the
cells through the tubes. HHBSS continued to ﬂow
through the pump tubes and onto the cells throughout
the experiment. The images were captured with an
ORCA-12AG (C4742-80-12AG) High-Res Digital Cooled
CCD Camera (Hamamatsu Photonics Corporation).
The total areas under the curve (AUC), which reﬂects
the amount of Ca2+ released (Berridge, 2007), were
analyzed to measure the vigor of the Ca2+ response.
The amplitude was expressed as the maximum increase
of the 340/380 ratio. The area under the Ca2+ peaks
was calculated in Origin (Microcal Software Inc.,
Northampton, MA, USA). Forty cells were used for each
experimental set up, taken from four diﬀerent coverslips
and from two diﬀerent seeding times.
Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and Western blotting
The cells were rinsed twice in PBS and immediately lysed
for 20 min on ice in cold radio-immunoprecipitation assay
(RIPA) lysis buﬀer containing 150 mM NaCl, 1%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris, (pH 8.0), supplemented with a
protease inhibitor cocktail containing 104 mM AEBSF,
80 lM aprotinin, 4 mM bestatin, 1.4 mM E-64, 2 mM
leupeptin, and 1.5 mM pepstatin A. The procedure was
performed according to Persson et al. (2005). Separate
aliquots were collected to determine the protein
concentration. All of the samples were analyzed for the
total protein content, and 20 lg of the total protein from
each sample was loaded into each lane of the gel. b-
Actin was used as control for equal loading.
SDS–PAGE was conducted using the Novex pre-cast
gel system (Invitrogen) according to the manufacturer’s
recommendations using 4–12% Bis-Tris gels
(Invitrogen) at 200 V for 50 min. The separated proteins
were transferred at 30 V for 60 min to a nitrocellulose
membrane (Invitrogen) using NuPAGE transfer buﬀer
(Invitrogen) supplemented with methanol and NuPAGE
antioxidant. The membranes were rinsed twice with
distilled water, and the proteins were visualized with
Ponceau S solution (Sigma). The proteins were blocked
with 5% fat-free skim milk (Semper AB, Sundbyberg,
Sweden) in Tris-buﬀered saline (TBST; 50 mM Tris–HCl,
150 mM NaCl, and 0.05% Tween) for 60 min at room
temperature. The membranes were probed with a
mouse monoclonal primary antibody against Na+/K+-
ATPase (a-subunit) diluted 1:250, washed 4 for 2 min
with TBST, followed with the secondary horseradish
peroxidase (HRP)-conjugated antibody, donkey anti-
mouse F(ab0)2 fragment (Jackson ImmunoResearch)
diluted 1:10,000, also washed several times in TBST.
All of the primary and secondary antibodies were diluted
in 5% fat-free skim milk in TBST. The antibody-bound
protein was detected with an enhanced
chemiluminescence kit (PerkinElmer Inc., Waltham, MA,
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Actin visualization
The astrocyte cytoskeleton was stained with an
Alexa488-conjugated phalloidin probe. Some of the
cultures were incubated with 10 ng/ml LPS for 24 h.
Other cultures were incubated with naloxone (1012 M),
endomorphin-1 (106 M), and/or levetiracetam (104 M)
for 30 min before they were incubated with LPS and the
proposed combination. The cultures were ﬁxed with 4%
paraformaldehyde and made permeable with PBS
(Invitrogen) containing 1% BSA and 0.05% saponin
followed by an Alexa568-conjugated phalloidin probe
(Invitrogen) diluted 1:40 in PBS supplemented with 1%
BSA. The coverslips were rinsed three times in PBS
and mounted on microscope slides using Dako’s
ﬂuorescent mounting medium (Dako) before being
viewed with a ﬂuorescence dry-objective lens attached
to an inverted Nikon Optiphot-2 microscope.
Cytokine release
The co-cultured astrocytes were stimulated for 24 h with
10 ng/ml LPS diluted in non-supplemented minimum
essential medium (MEM) to measure IL-1b release. The
inserts with endothelial cells were removed immediately
before incubation. The cells were incubated with
levetiracetam (1012–104 M) or a combination of
naloxone (1012 M), endomorphin-1 (106 M), and
levetiracetam (104 M) for 30 min prior to LPS treatment
and remained in the medium throughout the experiment.
The control (i.e., untreated) cells were maintained in
non-supplemented MEM. The supernatants were
collected for an enzyme-linked immunosorbent assay
(ELISA), and the cells were analyzed for protein
concentration.
Rat IL-1b (Nordic Biosite, Ta¨by, Sweden) was used
according to the manufacturer’s instructions to measure
the amount of cytokine with ELISA. Between every
incubation step, several washes were performed. The
protein concentration was determined as described
below. The amount of IL-1b release was correlated to
the amount of protein in each well.
Protein determination
The protein determination assay was performed in
accordance with the manufacturer’s instructions using a
detergent compatible (DC) Protein Assay (Bio-Rad,
Hercules, CA, USA) based on the method used by
Lowry et al. (1951) with minor modiﬁcations. The
standard (0–4 mg/ml BSA) and samples were mixed
with the reagents, incubated for 15 min at room
temperature, read at 750 nm with a Versa-max
microplate reader, and analyzed using SoftMax Pro 4.8
from Molecular Devices (Sunnyvale, CA, USA).
Statistics
Diﬀerences across the diﬀerent treatments were identiﬁed
using a one-way analysis of variance (ANOVA) followedby Dunnett’s multiple comparisons test. The error bars
represent the standard error of the mean (SEM).
RESULTS
Glutamate-evoked Ca2+ responses were increased
with LPS and attenuated by a combination of
naloxone, endomorphin-1, and levetiracetam
The astrocytes were stimulated with glutamate (104 M),
and Ca2+ imaging experiments were performed on 15-
to 17-day-old co-cultured astrocytes. The endothelial
cell inserts were removed just before the experiments.
All of the cells responded, n= 40. The AUCs were
calculated, and the number of peaks was counted
(Fig. 2A, B).
The astrocytes incubated with LPS (10 ng/ml) for 24 h
showed an increase in glutamate-evoked Ca2+ signaling.
The AUC was signiﬁcantly increased (P< 0.001) as well
as the number of peaks. All cells responded, n= 40
(Fig. 2A, B). Endomorphin-1 attenuated the glutamate
signaling (P< 0.05), and all cells responded, n= 40
(Fig. 2A, B). Naloxone (1012 M) alone or together with
endomorphin-1 (106 M) did not attenuate the
glutamate-upregulated Ca2+ oscillations, n= 40
(Fig. 2A, B). Levetiracetam (104 M) attenuated the
glutamate signaling (P< 0.001), and all cells
responded, n= 40 (Fig. 2A, B). The combination of
naloxone, endomorphin-1, and levetiracetam attenuated
the glutamate signaling (P< 0.001), and all cells
responded (Fig. 2A, B).
The results show that a combination of endomorphin-
1, naloxone in ultralow concentration, and levetiracetam
fully attenuated the LPS-induced glutamate Ca2+
transients.
Na+/K+-ATPase expression was decreased by LPS
and increased by a combination of naloxone,
endomorphin-1 and levetiracetam
The expression of Na+/K+-ATPase for cultures
incubated with LPS for 24 h was studied using Western
blot analysis. The expression of Na+/K+-ATPase was
decreased (P< 0.05) in the cultured cells and was
increased when the cells were incubated with a
combination of naloxone, endomorphin-1, and
levetiracetam (P< 0.01, n= 6, Fig. 3A). None of these
agents alone showed any eﬀect on the expression of
Na+/K+-ATPase (Fig. 3B).
These results show that a combination of
endomorphin-1, naloxone in ultralow concentration, and
levetiracetam increased the Na+/K+-ATPase activity.
IL-1b release was decreased by levetiracetam
The cultures were pre-incubated with levetiracetam
(1012–104 M) 30 min prior to incubation with LPS
(10 ng/ml) and levetiracetam for 24 h. Levetiracetam
(104 M) reduced the LPS-induced increase in IL-1b
(P< 0.05, n= 4, Fig. 4). IL-1b release after LPS
stimulation was 4.3 ± 0.5 ng/ml and was set to 100%.
The cultures were pre-incubated with a combination of
naloxone (1012 M), endomorphin-1 (106 M), and
Fig. 2. Glutamate-evoked Ca2+ oscillations. All cells were stimulated
in a Ca2+ imaging system. The cells were incubated with a Ca2+-
sensitive ﬂuorophore probe (Fura-2/AM). Glutamate (104 M) elicited
Ca2+ responses in the astrocytes and was used as control. (A) The
areas under the Ca2+ peaks (AUC) of the Ca2+ transients were
calculated. The cells incubated with LPS (10 ng/ml) for 24 h showed
increased Ca2+ signaling in the form of oscillations. The cells pre-
incubated with a combination of naloxone (Nal) (1012 M), endomor-
phin-1 (EM-1) (106 M), and levetiracetam (Lev) (104 M) for 30 min
before they were incubated with a combination of LPS (10 ng/ml),
Nal, EM-1, and Lev for 24 h showed a signiﬁcant decrease in the
glutamate-evoked Ca2+ transients. Cells pre-incubated with Nal, a
combination with Nal and EM-1, for 30 min before they were
incubated with a combination of LPS and the respective substances
for 24 h did not attenuate the glutamate-upregulated Ca2+ transients.
Cells pre-incubated with EM-1 or Lev attenuated the glutamate-
upregulated Ca2+ transients. (B) The number of peaks was counted
for each cell. Statistical analysis: The level of signiﬁcance was
analyzed using a one-way ANOVA followed by Dunnett’s multiple
comparisons test. ⁄P< 0.05, ⁄⁄⁄P< 0.001, n.s. = not signiﬁcant.
Fig. 3. Na+/K+-ATPase expression. The cultures were incubated
with LPS (10 ng/ml) for 24 h. The Na+/K+-ATPase expression was
decreased compared with controls. (A) The cells were pre-incubated
with a combination of naloxone (Nal) (1012 M), endomorphin-1 (EM-
1) (106 M), and levetiracetam (Lev) (104 M) for 30 min before they
were incubated with a combination of LPS (10 ng/ml), Nal, EM-1, and
Lev for 24 h. The Na+/K+-ATPase expression increased with the
cocktail. Na+/K+-ATPase appears as a band just below 110 kDa. (B)
Nal, EM-1 or Lev alone did not show any eﬀect. Statistical analysis:
The level of signiﬁcance was analyzed using a one-way ANOVA
followed by Dunnett’s multiple comparisons test. ⁄⁄P< 0.01,
⁄P< 0.05. n= 6.
540 L. Block et al. / Neuroscience 250 (2013) 536–545levetiracetam (104 M) 30 min prior to incubation with
LPS (10 ng/ml), naloxone, endomorphin-1, and
levetiracetam for 24 h. The LPS-induced increase in IL-
1b was decreased (P< 0.001, n= 4, Fig. 5). Naloxone
alone did not decrease the IL-1b release (Forshammar
et al., 2011) nor did endomorphin-1 or a combination of
naloxone and endomorphin-1. Data are not shown.The results show that levetiracetam decreased the IL-
1b release, and that the combination of the three drugs
did not have any further inﬂuence on the release.Actin ﬁlaments
The astrocytes were stained with an Alexa488-conjugated
phalloidin probe. The untreated cultures were dominated
by F-actin organized in stress ﬁbers (control). The
cultures incubated with LPS (10 ng/ml) for 24 h showed
Fig. 4. IL-1b release. The cultures were pre-incubated with leveti-
racetam (Lev) (1012–104 M) 30 min prior to incubation with LPS
(10 ng/ml) and Lev for 24 h. Lev (104 M) reduced the LPS-increased
IL-1b concentration. Statistical analysis: The level of signiﬁcance was
analyzed using a one-way ANOVA followed by Dunnett’s multiple
comparisons test. ⁄P< 0.05. n= 6.
Fig. 5. IL-1b release. The cultures were pre-incubated with a
combination of naloxone (Nal) (1012 M), endomorphin-1 (EM-1)
(106 M), and levetiracetam (Lev) (104 M) 30 min prior to incubation
with LPS (10 ng/ml) and Nal + EM-1 + Lev for 24 h. The LPS-
induced increase in IL-1b was decreased. Statistical analysis: The
level of signiﬁcance was analyzed using a one-way ANOVA followed
by Dunnett’s multiple comparisons test. ⁄⁄⁄P< 0.001. n= 6.
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ring structures were more pronounced. Naloxone
(1012 M) as well as a combination of naloxone and
endomorphin-1 (106 M) prevented the restructuring of
the actin ﬁlaments (Fig. 6). The cells were pre-incubated
with a combination of naloxone, endomorphin-1, and
levetiracetam (104 M) for 30 min before they were
incubated with a combination of LPS (10 ng/ml),
naloxone, endomorphin-1, and levetiracetam for 24 h.
This combination prevented the restructuring of the actinﬁlaments even more robustly (Fig. 6). Levetiracetam can
also prevent the restructuring of actin ﬁlaments in the
cytoskeleton; however, the combination of the three
substances showed the most optimal result.
The results show that the combinations of naloxone
and endomorphin-1, as well as naloxone, endomorphin-
1 and levetiracetam equally prevented the restructuring
of actin ﬁlaments.DISCUSSION
We have identiﬁed four parameters, Ca2+ signaling in the
astrocyte networks, Na+/K+-ATPase activity, IL-1b
release, and actin ﬁlament organization, which take part
in mechanisms underlying or contributing to
neuroinﬂammation. The astrocytes are potential targets
during the inﬂammatory state (Forshammar et al., 2011;
Block et al., 2012). To achieve the full protective eﬀects,
a combination of treatments is required. It seems
important to maintain the extracellular concentration of
pro-inﬂammatory cytokines, such as IL-1b, at a low
level, which can be accomplished with levetiracetam. In
addition, it seems important to reduce the increased
extracellular glutamate concentration, which stimulates
an increased propagation of astrocyte intercellular Ca2+
waves. This is partly possible with endomorphin-1 and
ultralow concentrations of naloxone. The low protein
level and activity of Na+/K+-ATPase has to be
increased, which can be achieved through a decreased
activation of the Gs protein and an increased activation
of the Gi/o protein. The actin ﬁlaments, which are
disorganized, will be restored. However, to achieve
these features, a combination of these substances is
necessary for the restoration of the cellular parameters
disrupted by inﬂammation.
During inﬂammation and when cells are induced with
inﬂammatory agents, Ca2+ signaling in the astrocyte
networks is disturbed. There is an increased release of
IL-1b, which results in gap junction inhibition (Kim et al.,
2010). There is also an increased release of ATP, which
provides a parallel system for intercellular Ca2+
communication between astrocytes (Fields and
Burnstock, 2006) and triggers the release of glutamate
(Domercq et al., 2006).
The inﬂammatory inducer LPS changed the
glutamate-evoked Ca2+ transients from single peaks to
Ca2+ oscillations when the astrocytes were incubated
with LPS for a long time. This means that the
intracellular Ca2+ release from the endoplasmic
reticulum increased, which leads to an overstimulation
of the Gq mGluR5-dependent astrocyte Ca
2+ elevations
followed by the propagation of intercellular Ca2+ waves
(Bradley et al., 2009). Another cellular parameter that is
altered by LPS is Na+/K+-ATPase, which results in the
downregulation and disorganization of actin ﬁlaments
(Forshammar et al., 2011).
The challenge is to reverse inﬂammation-induced
changes to return cellular homeostasis back to normal
physiological levels (Watkins and Maier, 2003; Hansson,
2006, 2010; Zhuo et al., 2011). Several substances
have been suggested for this purpose, and a huge
Fig. 6. Actin ﬁlaments. The astrocytes were stained with an Alexa488-conjugated phalloidin probe. The untreated culture was dominated by F-actin
organized into stress ﬁbers (control). The cultures incubated with LPS (10 ng/ml) for 24 h showed a more diﬀuse organization of actin ﬁlaments, and
the ring structures were more pronounced. Naloxone (1012 M) as well as a combination of naloxone and endomorphin-1 (EM-1) (106 M), or
levetiracetam (Lev) (104 M) prevented the restructuring of actin ﬁlaments. Cells pre-incubated with a combination of Nal, EM-1, and Lev for 30 min
before they were incubated with a combination of LPS (10 ng/ml), Nal, EM-1, and Lev for 24 h prevented also the restructuring. Scale bar = 50 lm.
Representative images are presented from at least three diﬀerent seedings.
542 L. Block et al. / Neuroscience 250 (2013) 536–545number of experiments have been performed to ﬁnd an
agent that possesses all the properties necessary to
restore inﬂammation-reactive cells (Tchivileva et al.,
2009; Nadeau et al., 2011; Wen et al., 2011).
The CNS is sensitive to opiates, and endogenous
opioids modulate cellular proliferation. The classical
opioid system is best known for its eﬀects on
nociception (Fields, 2004); however, it is also important
for modulating the immune system and releasing Ca2+
from intracellular stores. These eﬀects are mediated by
G protein-coupled opioid receptors (Uhl et al., 1994;
Hansson et al., 2008), which can be activated by
inﬂammatory stimuli (Chen and Marvizo´n, 2009;Vanderah, 2010). It is known that l-opioid receptors
preferentially couple to pertussis toxin (PTX)-sensitive G
proteins, Gi/Go, and inhibit the adenylyl cyclase/cAMP
pathway (Connor and Christie, 1999). A switch in G
protein coupling from Gi/Go to Gs proteins, which
activates the adenylyl cyclase/cAMP pathway, has been
shown to be elicited by the chronic administration of
opioids in dorsal root ganglion neurons in culture (Crain
and Shen, 1995) and in vivo in rats (Wang et al., 2005).
The attenuation of Gi/Go protein coupling is involved in
the initiation and/or maintenance of allodynic pain
(Womer et al., 1997). Therefore, it seems important to
stimulate the Gi/Go proteins and decrease the Gs
L. Block et al. / Neuroscience 250 (2013) 536–545 543protein activities. Naloxone in ultralow concentrations
inhibited the l-opioid receptor/Gs coupling and
stimulated the l-opioid receptor Gi/Go protein (Tsai
et al., 2009). Ultralow doses of naloxone in combination
with morphine attenuate chronic morphine-induced Gs
protein coupling in rats (Shen and Crain, 1997; Wang
et al., 2005), whereas higher concentrations
antagonized excitatory and inhibitory opioid receptors
(Crain and Shen, 1995). Ultralow concentrations of
naloxone also inhibit the disturbed astrocyte activation
(Forshammar et al., 2011; Block et al., 2012). These
results indicate that ultralow doses of naloxone in
combination with a l-opioid receptor agonist, such as
morphine or endomorphin-1, increase Gi/Go protein
coupling and suppress neuroinﬂammation by reducing
the excitatory Gs protein-coupled opioid receptors in rats
(Tsai et al., 2009), patients (Maxwell et al., 2005), and
astrocyte cultures (Block et al., 2012). This combination
switches the l-opioid receptor coupling from Gs protein
to Gi/Go protein, and ultralow concentration of naloxone
prevents the switch back again.
Downregulation of Na+ transporters has been
observed in diﬀerent inﬂammatory cellular systems,
which indicates a dysfunction of Na+/K+-ATPase
activity and can lead to increased intracellular Na+
concentrations (Schmidt et al., 2007). Astrocytes have a
strong resistance to Na+ inﬂux only when Na+/K+-
ATPase activity is maintained (Takahashi et al., 2000).
Na+/K+-ATPase is stimulated by low concentrations
of naloxone by the activation of the Scr/epidermal
growth factor receptor (EGFR) intracellular pathway,
which increases the intracellular Ca2+ concentration
through the phospholipase C/inositol 1,4,5-trisphosphate
receptor (IP3) pathway (Zhang et al., 2008). Ultralow
concentrations of naloxone prevented the inﬂammation-
induced downregulation of Na+/K+-ATPase in
astrocytes, and stimulated the intracellular Ca2+ release
(Forshammar et al., 2011). Data indicate that
endomorphin-1 as well as morphine indirectly stimulates
Na+/K+-ATPase activity by activating l-opioid
receptors and Gi/Go proteins (Masocha et al., 2002;
Horvath et al., 2003). This suggests that the
combination of ultralow concentrations of naloxone and
endomorphin-1 or morphine, stimulates Gi/Go protein
and Na+/K+-ATPase activities.
The involvement of the cytoskeleton in controlling the
plasma membrane microdomains and endoplasmic
reticulum complex seems to be of importance. The
adaptor protein ankyrin B is associated with the Na+
pump and with endoplasmic reticulum proteins, such as
the IP3 receptor. The main cytoplasmic matrix of
proteins, spectrin and actin, are attached to ankyrin B.
An intact cytoskeleton is required for the propagation of
astrocyte Ca2+ waves (Cotrina et al., 1998;
Forshammar et al., 2011), and disruption abolishes the
Ca2+ oscillations by changing the balance between the
Ca2+ regulating processes (Sergeeva et al., 2000),
which is observed when astrocytes are aﬀected by LPS.
Naloxone at ultralow concentrations prevented the
restructuring of the actin ﬁlaments in the cytoskeleton of
astrocytes (Forshammar et al., 2011). Filamin A,cross-linking cytoplasmic actin ﬁlaments, has been
found to regulate cell signaling by interacting with
several receptors including l-opioid receptors. Naloxone
binds to a pentapeptide segment of ﬁlamin A, and in
ultralow concentrations naloxone prevents morphine’s
coupling to the Gs protein (Wang and Burns, 2009). This
shows the importance of a working Na+ pump, which is
coupled to the cellular cytoskeleton.
The biosynthesis of IL-1b is complex and regulated at
multiple levels. The increased release of IL-1b observed
under inﬂammatory conditions reduces intercellular
communication by the passage of IP3 through gap
junctions in astrocyte networks (Retamal et al., 2007).
Therefore, neuroprotective Ca2+ signaling is inhibited.
As a result, the other Ca2+ signaling pathway, the
extracellular ATP pathway, increases (Froger et al.,
2010).
A substance that has been observed to decrease IL-
1b release is the anti-epileptic drug levetiracetam
(Keppra). Levetiracetam has anti-inﬂammatory
properties and has been shown to restore functional gap
junction coupling in astrocytes under inﬂammatory
conditions (Haghikia et al., 2008). Furthermore,
levetiracetam had the ability to decrease the enhanced
IL-1b level (Haghikia et al., 2008). Levetiracetam can
also normalize the membrane resting potential, and
prevent the restructuring of actin ﬁlaments in the
cytoskeleton (Stienen et al., 2010). We found also a
decrease of the enhanced IL-1b level at higher
concentrations, and restoration of the actin ﬁlaments.
Microglia were in fact still minor after treatment with
LPS for 24 h, evidenced by a sparse OX42 staining, and
the production of IL-1b can be in majority attributed to
astrocytes.
Levetiracetam restored the increased Ca2+
oscillations; however, in combination with endomorphin-
1 and an ultralow concentration of naloxone, the eﬀect
was more pronounced. Similar results were observed
regarding Na+/K+-ATPase. Concerning the IL-1b
release, naloxone alone (Forshammar et al., 2011) or in
combination with endomorphin-1 did not decrease
cytokine release. However, levetiracetam had some
restoring eﬀects on the actin ﬁlaments. In the absence
of a working astrocyte network, interactions between
neurons, astrocytes, and other cell types will be
problematic. The combination of ultralow concentrations
of naloxone, endomorphin-1, and levetiracetam,
switches the activation of the l-opioid receptor to Gi/o
protein coupling, which stimulates the Na+/K+-ATPase
activity and restores the actin ﬁlaments and the
intercellular Ca2+ signaling. The extracellular Ca2+
signaling decreases and so does the inﬂammatory
enhanced IL-1b release. These actions will lead to
neuroprotective intercellular Ca2+ signaling in the
astrocyte networks and will restore cellular homeostasis.CONCLUDING REMARKS
The present results are based on the ﬁndings that the
combination of a l-opioid receptor antagonist at ultralow
concentrations, a l-opioid receptor agonist, and an
544 L. Block et al. / Neuroscience 250 (2013) 536–545agent attenuating IL-1b release can restore the cellular
parameters altered by inﬂammation to the normal, non-
inﬂammatory state. This three-drug composition could
be clinically useful for treatment of long-term pain.CONFLICT OF INTEREST
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